deltatrials
Completed PHASE1 INTERVENTIONAL 6-arm NCT02496897

Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B

A Phase I, Randomized, Double-blind, Placebo-controlled, Multi-centre, Ascending-dose Trial to Evaluate the Safety, Tolerability and Immunogenicity of Vaccine FP-02.2 in HBeAg-negative Hepatitis B Patients as an add-on Treatment to Entecavir or Tenofovir.

Sponsor: Altimmune, Inc.

Conditions Hepatitis B
Interventions FP-02.2 Vaccine IC31® Adjuvant Placebo
Updated 12 times since 2017 Last updated: May 21, 2025 Started: Jul 31, 2015 Primary completion: Oct 13, 2017 Completion: Jun 5, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Hepatitis B and is currently completed. Altimmune, Inc. leads this study, which shows 12 recorded versions since 2015 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Jan 2017 – ~Jun 2017 · 5 months · monthly snapshotRecruiting~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshotRecruiting~Aug 2017 – ~Dec 2017 · 4 months · monthly snapshotRecruiting~Dec 2017 – ~Apr 2018 · 4 months · monthly snapshotActive Not Recruiting~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshotActive Not Recruiting~Jun 2018 – ~Feb 2019 · 8 months · monthly snapshotActive Not Recruiting~Feb 2019 – ~Jan 2021 · 23 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshotCompleted~Jun 2025 – ~Sep 2025 · 3 months · monthly snapshotCompleted~Sep 2025 – present · 10 months · monthly snapshotCompleted

Change History

12 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Jun 2025 — Sep 2025 [monthly]

    Completed PHASE1

  3. Sep 2024 — Jun 2025 [monthly]

    Completed PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  5. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

▶ Show 7 earlier versions

  1. Feb 2019 — Jan 2021 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  2. Jun 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE1

  3. Apr 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

  4. Dec 2017 — Apr 2018 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  5. Aug 2017 — Dec 2017 [monthly]

    Recruiting PHASE1

  6. Jun 2017 — Aug 2017 [monthly]

    Recruiting PHASE1

  7. Jan 2017 — Jun 2017 [monthly]

    Recruiting PHASE1

    First recorded

Jul 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Altimmune, Inc.
Data source: Altimmune, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations